Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani 2, 35100 Padova, Italy.
Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):72-5. doi: 10.1016/j.prostaglandins.2011.08.002. Epub 2011 Aug 11.
CYP450-dependent epoxyeicosatrienoic acids (EETs) are potent arterial vasodilators, while 20-hydroxyeicosatatraenoic acid (20-HETE) is a vasoconstrictor. We evaluated their role in the control of portal circulation in normal and cirrhotic (CCl(4) induced) isolated perfused rat liver. Phenylephrine (PE) and endothelin-1 (ET-1) increased portal perfusion pressure, as did arachidonic acid (AA), 20-HETE, and 11,12-EET. Inhibition of 20-HETE with 12,12-dibromododecenoic acid (DBDD) did not affect basal pressure nor the responses to PE, ET-1, or AA. However, inhibition of epoxygenase with miconazole caused a significant reduction in the response to ET-1 and to AA, without affecting neither basal pressure nor the response to PE. Hepatic vein EETs concentration increased in response to ET-1, and was increased in cirrhotic, compared to control, livers. 20HETE levels were non-measurable. Miconazole decreased portal perfusion pressure in cirrhotic livers. In conclusion, 20HETE and EETs increase portal resistance; EETs, but not 20-HETE, mediate in part the pressure response to ET-1 in the portal circulation and may be involved in pathophysiology of portal hypertension.
CYP450 依赖性环氧二十碳三烯酸 (EETs) 是强效的动脉血管舒张剂,而 20-羟二十碳四烯酸 (20-HETE) 则是血管收缩剂。我们评估了它们在正常和肝硬化(CCl4 诱导)离体灌注大鼠肝中对门脉循环控制的作用。苯肾上腺素 (PE) 和内皮素-1 (ET-1) 增加门脉灌注压,花生四烯酸 (AA)、20-HETE 和 11,12-EET 也是如此。用 12,12-二溴十二烯酸 (DBDD) 抑制 20-HETE 并不影响基础压力或对 PE、ET-1 或 AA 的反应。然而,用咪康唑抑制环氧合酶会导致对 ET-1 和 AA 的反应显著减少,而对基础压力或 PE 的反应没有影响。肝静脉 EETs 浓度在 ET-1 反应中增加,并且在肝硬化中比在对照组中增加。20-HETE 水平不可测量。咪康唑降低了肝硬化肝脏的门脉灌注压。总之,20-HETE 和 EETs 增加门脉阻力;EETs,但不是 20-HETE,部分介导了 ET-1 在门脉循环中的压力反应,可能参与了门脉高压的病理生理学。
Prostaglandins Other Lipid Mediat. 2011-8-11
Prostaglandins Other Lipid Mediat. 2003-10
Am J Physiol Gastrointest Liver Physiol. 2009-7
J Gastroenterol Hepatol. 1997-4
Prostaglandins Other Lipid Mediat. 2015-7
Int J Mol Sci. 2021-10-3
Prostaglandins Other Lipid Mediat. 2012-1-10
Adv Pharmacol. 2010
Pflugers Arch. 2010-3-12
J Lipid Res. 2009-4
Am J Physiol Heart Circ Physiol. 2006-10
Curr Opin Nephrol Hypertens. 2004-3